The Psychiatric Research Institute’s Interventional Psychiatry program offers pioneering treatments for depression, bipolar disorder and other mental health conditions. These treatments are FDA-approved and very effective in helping individuals recover from their conditions, particularly if these conditions have not improved from the use of antidepressants or psychotherapy.
To find out more about the Interventional Psychiatry Program, call (501) 686-6678. or email us at email@example.com. The program will accept referrals from a patient’s current psychiatrist by faxing a recent history to (501) 603-1860 to the attention of Interventional Psychiatry.
Here are some of the treatments offered by the program:
Electroconvulsive therapy is used for patients with severe mood disorders (depression and bipolar) that have not responded to other forms of treatment. When a disorder becomes this severe, it is referred to as treatment-resistant depression. Electroconvulsive therapy is a primary a treatment choice for treatment-resistant depression, psychotic depression and acute suicidality. Also, it can be an ideal choice for severe depression during pregnancy and afterwards (postpartum depression), thereby allowing minimal exposure of the baby to medications.
Electroconvulsive therapy involves brief electrical stimulation of the brain conducted while the patient is under anesthesia. The electroconvulsive therapy team of medical professionals at the Psychiatric Research Institute includes a psychiatrist, an anesthesiologist and a nurse, all highly trained and experienced.
Ketamine has been used primarily as an anesthetic since the 1960s. Recently, it has been shown in some individuals to dramatically improve the symptoms of patients with severe depression, especially those with suicidal thoughts. The Psychiatric Research Institute is currently using two forms of this drug to treat suicidal ideation and treatment resistant depression: